A candidate neuroimaging biomarker for detection of neurotransmission-related functional alterations and prediction of pharmacological analgesic response in chronic pain
Daniel MartinsiD, Mattia VeroneseiD, Federico TurkheimeriD, Matthew A. HowardiD, Steven WilliamsiD, Ottavia DipasqualeiD
Abstract
BackgroundChronic pain is a world-wide clinical challenge. Response to analgesic treatment is limited and difficult to predict. Functional MRI (fMRI) has been suggested as a potential solution. However, while most analgesics target specific neurotransmission pathways, fMRI-based biomarkers are not specific for any neurotransmitter system, limiting our understanding of how they might contribute to predict treatment response. MethodsHere, we sought to bridge this gap by applying Receptor-Enriched Analysis of Functional Connectivity by Targets (REACT) to investigate whether neurotransmission-enriched functional connectivity (FC) mapping can provide insights into the brain mechanisms underlying chronic pain and inter-individual differences in analgesic response after a placebo or duloxetine. Chronic knee osteoarthritis (OA) pain patients (n=56) underwent pre-treatment brain scans in two clinical trials. Study 1 (n=17) was a 2-week single-blinded placebo pill trial. Study 2 (n=39) was a 3-month double-blinded randomized trial comparing placebo to duloxetine, a dual serotonin-noradrenaline reuptake inhibitor. ResultsAcross two independent studies, we found that chronic pain OA patients present FC alterations in the FC related to the serotonin (SERT) and noradrenaline (NET) transporters, when compared to age-matched healthy controls. Placebo responders presented with higher pre-treatment dopamine transporter (DAT)-enriched FC than non-responders. Duloxetine responders presented with higher pre-treatment SERT and NET-enriched FC than non-responders. Pre-treatment SERT and NET-enriched FC achieved predictive positive values of duloxetine response up to 85.71%. ConclusionNeurotransmission-enriched FC mapping might hold promise as a new mechanistic-informed biomarker for functional brain alterations and prediction of response to pharmacological analgesia in chronic pain.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 28
- FWCI
- 1.84
- Field percentile
- top 15%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Brain and psychological determinants of placebo pill response in chronic pain patients
Étienne Vachon‐Presseau, Sara Berger, … A. Vania Apkarian·Nature CommunicationsPeer-reviewed·Aug 17, 2018
- Pain Stickiness in Complex Regional Pain Syndrome: A role for the Nucleus Accumbens
Andrew M. Youssef, Ke Peng, … Laura E. Simons·Neurobiology of PainPeer-reviewed·Jan 1, 2021
- The functional anatomy of nociception: effective connectivity in chronic pain and placebo responders
Sanjeev Nara, Marwan N. Baliki, … Dipanjan Ray·Journal of NeurosciencePeer-reviewed·May 9, 2025
- Pain-related opioidergic and dopaminergic neurotransmission: Dual Meta-Analyses of PET Radioligand Studies
Sergio Garcia Guerra, Andrea D. Spadoni, … Irina A. Strigo·Brain ResearchPeer-reviewed·Jan 1, 2022
- Sustained perturbation in functional connectivity induced by cold pain
Elena Makovac, Ottavia Dipasquale, … Matthew A. Howard·European Journal of PainPeer-reviewed·Jul 10, 2020
- Prolonged tonic pain in healthy humans enhances functional connectivity of descending pain modulation networks involving the amygdala, periaqueductal gray and parabrachial nucleus to cortical sensory-discriminative areas
Timothy J. Meeker, Anne‐Christine Schmid, … David Anthony Seminowicz·bioRxiv·Aug 31, 2021